Hypoxia and oxidative stress can trigger MET expression or activation in HCC, and MET is involved in the resistance to antiangiogenic therapy [6, 7, 9, 10], its expression increasing in HCC cells resistant to sorafenib [11, 12]. The gene discussed is MET; the disease is hepatocellular carcinoma.